Roche gets approval for HPV self-collection solution
May 15, 2024—The FDA has approved Roche’s HPV self-collection solution for use with the company’s Cobas HPV test.
Webinars and Sponsored Roundtables — Register Now
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Industry News
FDA clears QIAstat-Dx respiratory syndromic testing panel
May 13, 2024—Qiagen announced that the FDA has cleared its QIAstat-Dx Respiratory Panel Plus syndromic test for clinical use.
FDA clears Halo AP Dx digital pathology platform
May 8, 2024—Indica Labs received FDA 510(k) clearance for its Halo AP Dx digital pathology platform for use in primary diagnosis.
Quest to acquire PathAI Diagnostics
May 1, 2024—Quest Diagnostics and PathAI announced a multifaceted collaboration designed to accelerate the adoption of digital and AI pathology innovations.
Leica gets 510(k) clearance for Aperio GT 450 DX
Leica Biosystems announced that its flagship digital pathology slide scanner, the Aperio GT 450 DX, has received FDA 510(k) clearance.
Labcorp wins bid for select assets of Invitae
April 26, 2024—Labcorp announced it will purchase select assets of genetics company Invitae for $239 million.
FDA clears Scopio digital bone marrow aspirate application
April 25, 2024—Scopio Labs announced it has been granted de novo clearance by the FDA for its Full-Field Bone Marrow Aspirate application for use on the company’s X100 and X100HT platforms.
FDA approves OncoReveal CDx on Illumina MiSeq Dx system
April 23, 2024—Pillar Biosciences announced that the FDA has approved the company’s premarket approval supplement application for the OncoReveal CDx pan-cancer solid tumor in vitro diagnostic assay.
Leica publishes guide to good histology practice
April 22, 2024—Leica Biosystems has published “101 steps to better histology—a practical guide to good histology practice,” written by histology consultant Geoffrey Rolls.
Bruker to acquire NanoString Technologies for $392.6 million
April 19, 2024—NanoString Technologies announced that substantially all of its assets will be acquired by Bruker Corp.